Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma

J. Hardy; J. Tewhaiti-Smith; C. Baggott; J. Fingleton; Alex Semprini; M. Holliday; R. J. Hancox; M. Weatherall; R. Beasley; M. Harwood; A. Corin; C. Helm; T. Paterson; B. Poudel; M. Dyer; C. Jasinski; D. Sheahan; P. Sheahan; N. Gailer; J. Van Zuilen; A. Basa; C. Devereaux; K. Egan; S. Haughey; R. Marks; D. Venter; H. Zhang; K. Trevithick; M. Williams; C. Baggott; R. Beasley; I. Braithwaite; A. Eathorne; S. Ebmeier; J. Fingleton; D. Hall; J. Hardy; M. Harwood; M. Holliday; C. Houghton; S. Mane; J. Martindale; K. Oldfield; J. Pilcher; D. Sabbagh; P. Shirtcliffe; S. Snively; J. Sparks; A. Vohlidkova; M. Williams; P. Collins; S. Has-San; A. Lam; C. Lionnet; B. Montgomery; S. Moon; D. Quinn; D. Millar-Coote; J. Reid; N. Burton; T. Mullard; T. Tranquilino; E. Watson; J. Bell; J. Richmond; B. Krivan; C. Robertson; R.J. Hancox; M. Weatherall; S. Glensor; A. -C. Porrachia; H. K. Reddel

Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma

J. Hardy, J. Tewhaiti-Smith, C. Baggott, J. Fingleton, Alex Semprini, M. Holliday, R. J. Hancox, M. Weatherall, R. Beasley, M. Harwood, A. Corin, C. Helm, T. Paterson, B. Poudel, M. Dyer, C. Jasinski, D. Sheahan, P. Sheahan, N. Gailer, J. Van ZuilenA. Basa, C. Devereaux, K. Egan, S. Haughey, R. Marks, D. Venter, H. Zhang, K. Trevithick, M. Williams, C. Baggott, R. Beasley, I. Braithwaite, A. Eathorne, S. Ebmeier, J. Fingleton, D. Hall, J. Hardy, M. Harwood, M. Holliday, C. Houghton, S. Mane, J. Martindale, K. Oldfield, J. Pilcher, D. Sabbagh, P. Shirtcliffe, S. Snively, J. Sparks, A. Vohlidkova, M. Williams, P. Collins, S. Has-San, A. Lam, C. Lionnet, B. Montgomery, S. Moon, D. Quinn, D. Millar-Coote, J. Reid, N. Burton, T. Mullard, T. Tranquilino, E. Watson, J. Bell, J. Richmond, B. Krivan, C. Robertson, R.J. Hancox, M. Weatherall, S. Glensor, A. -C. Porrachia, H. K. Reddel

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes. METHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable. RESULTS: Seventy-two participants (8%) identified as Māori, 36 participants (4%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70). CONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.

Original language	English
Pages (from-to)	61-72
Number of pages	12
Journal	New Zealand Medical Journal
Volume	133
Issue number	1520
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hardy, J., Tewhaiti-Smith, J., Baggott, C., Fingleton, J., Semprini, A., Holliday, M., Hancox, R. J., Weatherall, M., Beasley, R., Harwood, M., Corin, A., Helm, C., Paterson, T., Poudel, B., Dyer, M., Jasinski, C., Sheahan, D., Sheahan, P., Gailer, N., ... Reddel, H. K. (2020). Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma. New Zealand Medical Journal, 133(1520), 61-72.

@article{0a48bb2940ee4e1a9e88f4e3ae8e868a,

title = "Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma",

abstract = "AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes. METHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable. RESULTS: Seventy-two participants (8%) identified as Māori, 36 participants (4%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70). CONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.",

author = "J. Hardy and J. Tewhaiti-Smith and C. Baggott and J. Fingleton and Alex Semprini and M. Holliday and Hancox, {R. J.} and M. Weatherall and R. Beasley and M. Harwood and A. Corin and C. Helm and T. Paterson and B. Poudel and M. Dyer and C. Jasinski and D. Sheahan and P. Sheahan and N. Gailer and {Van Zuilen}, J. and A. Basa and C. Devereaux and K. Egan and S. Haughey and R. Marks and D. Venter and H. Zhang and K. Trevithick and M. Williams and C. Baggott and R. Beasley and I. Braithwaite and A. Eathorne and S. Ebmeier and J. Fingleton and D. Hall and J. Hardy and M. Harwood and M. Holliday and C. Houghton and S. Mane and J. Martindale and K. Oldfield and J. Pilcher and D. Sabbagh and P. Shirtcliffe and S. Snively and J. Sparks and A. Vohlidkova and M. Williams and P. Collins and S. Has-San and A. Lam and C. Lionnet and B. Montgomery and S. Moon and D. Quinn and D. Millar-Coote and J. Reid and N. Burton and T. Mullard and T. Tranquilino and E. Watson and J. Bell and J. Richmond and B. Krivan and C. Robertson and R.J. Hancox and M. Weatherall and S. Glensor and Porrachia, {A. -C.} and Reddel, {H. K.}",

year = "2020",

language = "English",

volume = "133",

pages = "61--72",

journal = "New Zealand Medical Journal",

issn = "0028-8446",

publisher = "Pasifika Medical Association Group",

number = "1520",

}

Hardy, J, Tewhaiti-Smith, J, Baggott, C, Fingleton, J, Semprini, A, Holliday, M, Hancox, RJ, Weatherall, M, Beasley, R, Harwood, M, Corin, A, Helm, C, Paterson, T, Poudel, B, Dyer, M, Jasinski, C, Sheahan, D, Sheahan, P, Gailer, N, Van Zuilen, J, Basa, A, Devereaux, C, Egan, K, Haughey, S, Marks, R, Venter, D, Zhang, H, Trevithick, K, Williams, M, Baggott, C, Beasley, R, Braithwaite, I, Eathorne, A, Ebmeier, S, Fingleton, J, Hall, D, Hardy, J, Harwood, M, Holliday, M, Houghton, C, Mane, S, Martindale, J, Oldfield, K, Pilcher, J, Sabbagh, D, Shirtcliffe, P, Snively, S, Sparks, J, Vohlidkova, A, Williams, M, Collins, P, Has-San, S, Lam, A, Lionnet, C, Montgomery, B, Moon, S, Quinn, D, Millar-Coote, D, Reid, J, Burton, N, Mullard, T, Tranquilino, T, Watson, E, Bell, J, Richmond, J, Krivan, B, Robertson, C, Hancox, RJ, Weatherall, M, Glensor, S, Porrachia, A-C & Reddel, HK 2020, 'Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma', New Zealand Medical Journal, vol. 133, no. 1520, pp. 61-72.

TY - JOUR

T1 - Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma

AU - Hardy, J.

AU - Tewhaiti-Smith, J.

AU - Baggott, C.

AU - Fingleton, J.

AU - Semprini, Alex

AU - Holliday, M.

AU - Hancox, R. J.

AU - Weatherall, M.

AU - Beasley, R.

AU - Harwood, M.

AU - Corin, A.

AU - Helm, C.

AU - Paterson, T.

AU - Poudel, B.

AU - Dyer, M.

AU - Jasinski, C.

AU - Sheahan, D.

AU - Sheahan, P.

AU - Gailer, N.

AU - Van Zuilen, J.

AU - Basa, A.

AU - Devereaux, C.

AU - Egan, K.

AU - Haughey, S.

AU - Marks, R.

AU - Venter, D.

AU - Zhang, H.

AU - Trevithick, K.

AU - Williams, M.

AU - Baggott, C.

AU - Beasley, R.

AU - Braithwaite, I.

AU - Eathorne, A.

AU - Ebmeier, S.

AU - Fingleton, J.

AU - Hall, D.

AU - Hardy, J.

AU - Harwood, M.

AU - Holliday, M.

AU - Houghton, C.

AU - Mane, S.

AU - Martindale, J.

AU - Oldfield, K.

AU - Pilcher, J.

AU - Sabbagh, D.

AU - Shirtcliffe, P.

AU - Snively, S.

AU - Sparks, J.

AU - Vohlidkova, A.

AU - Williams, M.

AU - Collins, P.

AU - Has-San, S.

AU - Lam, A.

AU - Lionnet, C.

AU - Montgomery, B.

AU - Moon, S.

AU - Quinn, D.

AU - Millar-Coote, D.

AU - Reid, J.

AU - Burton, N.

AU - Mullard, T.

AU - Tranquilino, T.

AU - Watson, E.

AU - Bell, J.

AU - Richmond, J.

AU - Krivan, B.

AU - Robertson, C.

AU - Hancox, R.J.

AU - Weatherall, M.

AU - Glensor, S.

AU - Porrachia, A. -C.

AU - Reddel, H. K.

PY - 2020

Y1 - 2020

N2 - AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes. METHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable. RESULTS: Seventy-two participants (8%) identified as Māori, 36 participants (4%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70). CONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.

AB - AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes. METHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable. RESULTS: Seventy-two participants (8%) identified as Māori, 36 participants (4%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70). CONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.

UR - https://hdl.handle.net/1959.7/uws:78004

M3 - Article

SN - 0028-8446

VL - 133

SP - 61

EP - 72

JO - New Zealand Medical Journal

JF - New Zealand Medical Journal

IS - 1520

ER -

Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this